Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
复制标题
DOI：
10.1634/theoncologist.2014-0105
复制
发表时间：
2014-08-01
期刊：
影响因子：
5.8
通讯作者：
Haas, Naomi B.
中科院分区：
文献类型：
--
作者：
Pal, Sumanta K.;Haas, Naomi B.
目前，接受肾切除术治疗局限性肾细胞癌（RCC）的患者的标准治疗是放射学监测。随着许多新的靶向药物在转移性RCC中显示出活性，人们对探索相同药物在辅助治疗中的潜力产生了极大的兴趣。在此，我们讨论了RCC辅助试验的演变，从免疫治疗时代到靶向治疗时代。目前的研究的陷阱解决提供一个背景下解释即将到来的结果。最后，我们概述了在未来的辅助试验中纳入有前途的研究药物的途径，如PD-1（程序性死亡-1）抑制剂和MNNG转化基因抑制剂。肿瘤学家2014; 19：851-859
At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance. With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials. The Oncologist 2014; 19: 851-859